Navigation Links
Contract Research Organization WCCT Global Announces Acquisition of Early Phase Ophthalmology and Aesthetics Capabilities
Date:9/11/2013

Costa Mesa, California (PRWEB) September 11, 2013

WCCT Global, a contract research organization headquartered in Orange County, California, announced today the acquisition of OC Clinical Trials and Consulting, an early stage ophthalmology and cosmetology research practice. This acquisition provides WCCT Global with expanded early phase capabilities in its Ophthalmology Center of Excellence in the areas of Cornea & External Disease, Uveitis, Vitreoretinal Diseases, Glaucoma, Neuro-ophthlamology, Oculoplastics and pediatric ophthalmic conditions such as Strabismus and Amblyopia. Dr. Michael A. Sheety, WCCTG’s Medical and Surgery Director of Ophthalmology and Aesthetics says, “We are very excited to integrate this exceptional group of 6 Investigators and 5 study coordinators and research personnel into WCCT Global’s organization. The team brings more than 75 combined years of clinical and research experience in the areas of ophthalmology and aesthetics, and we’re confident that by joining this experience with WCCT’s solid infrastructure and reputation for conducting quality clinical trials, we will be able to provide unique capabilities in the area of ophthalmology and aesthetics to our Sponsors.” Dr. Sheety is board certified and fellowship trained in all aspects of refractive eye care including suture-less surgery and corneal transplantation. He has performed thousands of vision correction procedures, and also has extensive experience performing reconstructive and cosmetic eyelid surgery. In addition to his role overseeing WCCT Global’s Ophthalmology Research Center of Excellence, Dr. Sheety also serves as the chief consultant at the Children’s Hospital of Orange Country for all reconstructive eyelid injuries and the Grossman Burn Center at Western Medical Center in Santa Ana, CA. In addition, Dr. Sheety owns and operates one of the leading facilities in the treatment and prevention of dry eye disease. His dry eye facility conducts specialized treatments such as laboratory micro-analysis of tears and autologus growth-factor drops compounded for each patient to meet their exact needs.

With this acquisition, WCCT now owns and operates five total sites, including two Clinical Pharmacology Units (CPUs) with 180+ beds. WCCT’s ophthalmic patient database has grown 10-fold with patients of varying ages and demographics. Additionally, with an ophthalmology and optometry referral network of >20 facilities in southern California, WCCT now has direct access to more than 40,000 ophthalmology and optometry patients. In the cosmetology and aesthetics space, WCCT’s network has grown to >45 physicians throughout southern California. WCCT’s CEO, Dr. Kenneth T. Kim says, “WCCT is thrilled to have added Dr. Michael Sheety and the rest of the OC Clinical Trials research staff to the WCCT team. As the trend toward incorporation of patient populations earlier into clinical trials intensifies, WCCT is continuously looking to further expand our capabilities in patient populations. We want to provide Sponsors with the ability to run trials in Phase I and beyond in the ophthalmology therapeutic area, bridge quickly into patient populations in a proof of concept design, and then carry on into the larger, later stage patient efficacy trials in the blink of an eye.”

About WCCT Global:
WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow’s therapies to be available today" truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If you are interested in how WCCT Global can service one of your upcoming clinical studies, CLICK HERE.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11111241.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Florida Contracts L-A-B for Environmental Laboratory Assessment Services
2. Contract Research Organization WCCT Global Welcomes Lada Smirnova to the Executive Team as Chief Financial Officer
3. The Construction Audit and Cost Control Institute to Address "The Benefits of Auditing Construction Contracts and Contractors"
4. Study examines relationship of a commercial ACO contract with medical spending
5. Employment Lawyers at Gilman Law LLP Investigate Independent Contractor Misclassification in the State of Massachusetts Following the Recent Fedex Decision
6. Ben Davies, Chief Financial Officer at Octo Consulting Group was Announced Washington Business Journal (WBJ) 2013 Government Contracting CFO of the Year Award
7. Human Capital Resource, LLC, Adds Contract Staffing to Its Recruiting Services
8. BigToys Awarded Prestigious FAC79 Statewide Contract for Massachusetts
9. How Hiring a Painting Contractor in Michigan Can Save Homeowners Money
10. Specialty Drug Delivery Firm Integral BioSystems LLC to Participate in Contract Pharma Magazine’s 12th Annual Contracting & Outsourcing Conference & Tabletop Exhibition
11. Michael Melville of IntelliSoft Group Joins Partner Firm, Contract Logix, as Group CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... over twenty-four years, Doctors on Liens has published a directory of the top ... care. When the company started in 1997, the directory was a single page focusing ... now ten-page directory features a vast array of medical specialists stretching from Sacramento ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre ... unique properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved ... , Nothing Water has been available in several ShopRite and FoodTown stores in NJ ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare ... the honor of being selected as winners of multiple ... Healthcare Executives Website at the PLATINUM level, Blue Zones ... Module at the GOLD Level, and our proprietary 3ConneX ... At Simpson Healthcare Executives, we are excited to showcase ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
(Date:12/2/2016)... 2, 2016 Allergan plc (NYSE: AGN ... on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a variable ... Company will repurchase $10 billion of its ordinary shares. Approximately ...
Breaking Medicine Technology: